- Price
- $5.33
- Day
- +1.52%
- Mkt Cap
- $873.28M
- 52W Range
- $2.03 – $7.18
- Volume
- 2.53M
- Beta
- 1.17
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Expands Financial Capacity as Vonaprument and Tanruprubart Programs Advance Toward Registration Expands Financial Capacity as Vonaprument and Tanruprubart Programs Advance Toward Registration
Read full article
BRISBANE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on July 12, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).
Read full article
Annexon remains a high-risk/high-reward Buy, driven by two near-term blockbuster therapies, notably tanruprubart for Guillain-Barré syndrome (GBS). Tanruprubart achieved highly significant Phase 3 results, with a 2.4-fold GBS-DS improvement versus placebo and strong safety, positioning it for standard-of-care status. Regulatory filings are underway: MAA was submitted to EMA, with FDA BLA planned for 2026, supported by ongoing FORWARD and real-world evidence studies.
Read full article
BRISBANE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced an oral presentation on the neuroprotective effect of vonaprument at the American Society of Retina Specialists (ASRS) 44th Annual Scientific Meeting being held July 15–18, 2026 in Montréal, Québec, Canada.
Read full article